Published 7 days ago • loading... • Updated 7 days ago

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E

2 Articles

MarketBeat

Reposted by

BizToc

Center

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

7 days ago·Sioux Falls, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center1Last Updated7 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States 7 days ago on Tuesday, September 15, 2026.

Sources are mostly out of (0)

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

2 Articles

2 Articles

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Health: Vitiligo and Alopecia, Experts and Patients 'Are Recognized by Ssn for Access to New Therapies'

Medications: Vitiligo and Alopecia, Cordella (AbbVie) Are Committed to Improving Standards of Care Also

Obesity, Lombardy First Region to Implement National Law

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Every State Applied, and 40 Have Signed Medicaid Drug Pricing Deals Ahead of the September 30 Deadline

Similar News Topics

Similar News Topics

More stories like this

Health: Vitiligo and Alopecia, Experts and Patients 'Are Recognized by Ssn for Access to New Therapies'

Medications: Vitiligo and Alopecia, Cordella (AbbVie) Are Committed to Improving Standards of Care Also

Obesity, Lombardy First Region to Implement National Law

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Every State Applied, and 40 Have Signed Medicaid Drug Pricing Deals Ahead of the September 30 Deadline

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

2 Articles

2 Articles

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Health: Vitiligo and Alopecia, Experts and Patients 'Are Recognized by Ssn for Access to New Therapies'

Medications: Vitiligo and Alopecia, Cordella (AbbVie) Are Committed to Improving Standards of Care Also

Obesity, Lombardy First Region to Implement National Law

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Every State Applied, and 40 Have Signed Medicaid Drug Pricing Deals Ahead of the September 30 Deadline

Similar News Topics

Similar News Topics

More stories like this

Health: Vitiligo and Alopecia, Experts and Patients 'Are Recognized by Ssn for Access to New Therapies'

Medications: Vitiligo and Alopecia, Cordella (AbbVie) Are Committed to Improving Standards of Care Also

Obesity, Lombardy First Region to Implement National Law

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Every State Applied, and 40 Have Signed Medicaid Drug Pricing Deals Ahead of the September 30 Deadline

Bias Distribution

Factuality